Vitamina "A" y riesgos de teratogenicidad

Autores/as

  • Ramiro López Universidad Central del Ecuador
  • Kléver Sáenz Universidad Central del Ecuador
  • Carlos Torres Universidad Central del Ecuador

Resumen

Se realiza una revisión bibliográfica acerca de los posibles efectos indeseables y/o teratogénicos en general y del tubo neural en particular, que la Vitamina "A" y sus derivados retinoides sintéticos podrían producir, tanto a nivel experimental en animales, como hallazgos yatrogénicos en humanos, cuando mujeres en edad reproductiva o durante la gestación, ingieren altas dosis de vitamina A, debido a una mala prescripción médica o por automedicación.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Biografía del autor/a

Ramiro López, Universidad Central del Ecuador

Centro de Biomedicina, Unidad de Citogenética Humana, Facultad de Ciencias Médicas de la UC

Ministerio de Salud Pública, Instituto de Investigaciones para el Desarrollo de la Salud

Kléver Sáenz, Universidad Central del Ecuador

Centro de Biomedicina, Unidad de Citogenética Humana, Facultad de Ciencias Médicas de la UC.

Carlos Torres, Universidad Central del Ecuador

Centro de Biomedicina, Unidad de Citogenética Humana, Facultad de Ciencias Médicas de la UC

Citas

1. National Research Council: "Recomended dietary allowances". lOth ed. Washington, DC. National Academy Press, 1989; 84.

2. Underwood BA: "The safe use of vitamin A by women in the reproductive years. Report o f the International Vitamin A Consultative groUp. Ápril 1986. Washington the Group, 1986.

3. Teratology Society: "Recommendations for Vitamin A use in pregnancy (position statement)". Teratol, 1987; 35: 269-275.

4. Pinnock C, Alderman Ch P: "The potential for teratogenicity of vitamin A and its congeners". The Medical Journal of Australia, 1992; 157: 804-809.

5. Laurence KM: "Prevention o f Neural Tube Defects by Improvement in maternal diet and Preconceptional Folie Acid Suppléméntatión". Prevention o f Physical and Mental Congenital Defects, Part B; Epydemiology, Early Detection and Therapy, and Environmental Factors, 1985; 383-388.

6. Laurence KM, Campbell H, James N: "The role o f improvement in maternal diet and Preconceptional Folie Acid .Supplementation in the Prevention of neural Defects. In Dobbing J, eds: "Prevention of Spina Bifida and other Neuronal Tube Defects" London: Academic Press, 1983; 85-106.

7. Godfrey PO, Erickson JD: "Vitamin A and Birth Defects. Continuing Caution is Needed." N. Engl J Med, 1995; 21(333): 1414-1415.

8. USA: Recommendations for the use of folie acid to reduce the riumber o f cases o f spina bifida and other neural tube defects. MMWRB Morb Mortal Wkly Rep, 1987; 36: 80-82.

9. USA: Department o f health and Human Semces, Public Health Service, Center for Disease Control. Recommendations for the use of folie acid to reduce the number o f cases o f spine bifida and other neural tube defects. MMWR, 1 9 92;41:1-7.

10. Pérez-Escamilla R: " Periconcéptional Folie Acid and Neural Tube Defects: Public Health Issues". Bulletin od PAHO, 1995;. 29(3): 250-259.

11. Rothman K, Moore L, Singer M, et al. "Teratogenicity of High Vitamin A Intake". N Engl J Med, 1995; 21(333): 1369-1373.

12. Xui-Dao D, Chen A, Reidy J, ét al: "Folie acid and chromosome breakage". MutationRes, 1986; 174: 115-119.

13. Wald NJ, Hackshaw AK, Stone R, Nefertriti A: "Blood folie acid a,nd vitamin B12 in relation to neural tube defects" Br J Obstet Gynaecol, 1996; 103: 319- 324.

14. Blot L, Rey A, Kaltwasser JP, et al: "Folate and Iron Deficiencies in Mothers andThéir Newbom Children". Matemo-fetal Relations in Iron and Foliate Deficiencies. Springer-Verlag, 1982; 297-303.

15. Gillberg Ch, Wahlstrom J, Johansson R, et al: "Folie Acid as an adjunct in the treatment o f children with the autism fragile-X syndroffie :(ApRAX)". Developmental Mediciñe árid Child Ñeurology, 1986; 28: 624-627.

16. Blot L, Papiemik E, Kaltwasser JP, Wemer E, Techemia G: "Influence of routine administration o f folie acid and iron during pregnancy". Gynecol Obstet Invest, 1981; 12: 294.

17. Baumslag N, EdelsteinT, Metz J: "Reduction of incidence o f prematurely by folie acid supplementation in pregnancy". Br Med J, Í970; 1: 16.

18. Wolbach SB, Howe PR: "Tissue changes Following deprivation o f fat soluble A vitamin". J Exp Med, 1925; 42: 753-777.

19. Chytil F: "The lungs and vitamin A". A. Am J Physiol, 1992; 262: 517-527.

20. Studer M, Poperl H, Marshall H, et al: " Role of a conserved retinoic acid response element in rhombomere restriction o f Hoxb-l'\ Science, 1994; 265: 728-1732.

21. Bigby M, Stem RS: "Adverse reactions to isotretionin". J Am Acad Dermatol, 1988; 18: 543-552.

22. Waíren EW, Kinandera U: "Use o f retinoids in the treatment o f psoriasis". Clin Pharm, 1989: 8: 344-351.

23. Lucek RW, Colbum WA: "Clinical pharmocokinetics o f the retinoids". Clin Pharmacokinétic, 1985; 10: 38-62.

24. Geeleñ JA: "Hypervitaminosis A induced teratogenesis. CRC; Crit Rev Toxicol, 1979; 6: 351-375.

25. Jarvis BL, Johnston MC, Sulick KK: "Congenital malformations of the external middle an inner earproduced by isotretionin exposure in mouse embryos". Otolaryngol Head Neck Surg, 1990; 102: 391-401.

26. Da Costa D, de Fária G, Dias J, Bariani R: Acao Teratogena de Hipervitaminose A, com especial enfase sobre o globo ocular erri fetos.de ratos". Revista Goiana de Medicina, 1991; 37: 15-22.

27. Brentegani L, Sala M, Lopes R: "Estudio morfométrico y estereólógico de las alteraciones provocadas por hipervitaminosis A eb la glándula submandibular del hámster". Rev Fac Farm Odont Rib Preto, 1987; 144-147.

28. ILADIBA: "Exceso de vitamina A se asocia con desarrollo de de defectos congénitos", 1995; 63.

29. Vogt HJ, Ewers R: "13-cis-retinoic acid and spermatogenesis investigations by spermatólogy and impulse cytophotometry". Hautartz, 1985; 36: 281-286.

30. Rosa FW: "Teratogenicity of Isotretionin". Lancet, 1983; 2; 513.

31. Lammer E, Chen D, Hoar R, et al: "Retinoic acid embryophaty". N Engl J Med, 1985; 313: 837-841.

32. Doering PL, Araujo OE, Frohnapple DJ, et al: "Pattems o f prescribing isotretionin: focus on women of childbeanng potential". Ann Pharmacother,1992; 26: 155-161.

33. Stem RS: "When a uniquely effective drug is teratogenic. The case o f isotretionin". N Engl J Med, 1989; 320: 1007-10Ó9.

34. Alarcón M, Jonckree M, Sánchez de Molina D, cois: "Modificaciones dél Metabolismo proteico en la hipervitaminosis A aguda, en ratas". Acta Cient, 1986; 37(2): 162-169.

35. Nelsoñ M: (editorial). "Vitamina A liver consumption and risk of birth defecls". BMJ, 1990; 301: 1176.

36. Camera G, Pegfiasco P: "Ear malformation in baby bomto mother using tretinoin cream (letter)". Lancet, 1982; 339: 687.

37. Lammer EJ: "Embryóphathy in an infant conserved oné year after termination of maternal etretinate". Lancet 1988; 2: 1080-1081.

38. Martiñez-Frias ML, Salvador J: "Epidemiological aspeets o f prenatal exposure to high doses of Vitamin A in Spain". Eur J Epidemiol, 1990; 6: 118-123.

39. Werler MM, Lammer EJ, Rosenberg, L, Mitchel AA: "Maternal vitamin A supplementation in relation to selected birth defects". Teratology, 1990; 42: 497-503.

40. Choo V: "High-dose retinol associated with birth defects". Lancet, 1995; 36: 1027.

Descargas

Publicado

2017-06-09

Cómo citar

1.
López R, Sáenz K, Torres C. Vitamina "A" y riesgos de teratogenicidad. Rev Fac Cien Med (Quito) [Internet]. 9 de junio de 2017 [citado 19 de diciembre de 2024];22(1):9-11. Disponible en: https://revistadigital.uce.edu.ec/index.php/CIENCIAS_MEDICAS/article/view/837

Artículos más leídos del mismo autor/a